SCHEMBL6547864

SCHEMBL6547864

CCON=C(C)c1ccc(OCCOc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.35
FURIN P09958 1/20 0.34
GAA P10253 2/20 0.33
MAPT P10636 1/20 0.33
ALDH1A1 P00352 1/20 0.32
LMNA P02545 2/20 0.32
PTBP1 P26599 1/20 0.32
L3MBTL1 Q9Y468 3/20 0.31
MAPK1 P28482 1/20 0.31
ORAI1 Q96D31 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
FFAR1 O14842 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
THRA P10827 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6548597 0.97 HTT (0.39) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6548681 0.97 HTT (0.39) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6549633 0.96 HTT (0.38) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6548310 0.96 HTT (0.38) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6547887 0.91 HTT (0.39) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6548442 0.91 HTT (0.39) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6548389 0.91 HTT (0.37) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6549002 0.89 HTT (0.33) HTTSMN1; SMN2LMNAPTBP1NPC1
SCHEMBL6547693 0.88 HTT (0.41) HTTSMN1; SMN2FURINGAAMAPT
SCHEMBL6549004 0.87 NPC1 (0.35) HTTSMN1; SMN2MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 HTT 4052/4885SMN1; SMN2 2474/4885FURIN 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.